Inhibikase Therapeutics(IKT)
$1.32+0.02 (+1.54%)
IKT
Inhibikase Therapeutics financials statements
$1.32
At close:+0.02 (+1.54%)
Want to see IKT full AI Analyst Report?
Inhibikase Therapeutics (IKT) Ratios
380 Followers
Inhibikase Therapeutics Ratios
IKT's free cash flow for Q3 2026 was $-17.35M. For the 2026 fiscal year, IKT's free cash flow was increased by $0.00 and operating cash flow was $-17.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 |
| Quick Ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 |
| Cash Ratio | 16.77 | 15.13 | 2.67 | 1.95 | 10.05 |
| Solvency Ratio | -5.81 | -7.36 | -5.34 | -4.63 | -0.00 |
| Operating Cash Flow Ratio | -3.35 | -5.13 | -5.26 | -4.70 | -3.53 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -47.37 | 0.00 | -57.44 |
| Net Current Asset Value | $ 171.81M | $ 94.72M | $ 10.68M | $ 20.47M | $ 38.42M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.04 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.06 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.05 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.04 | 1.32 | 1.19 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -52.16 | -242.40 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -243.49 | -741.16 |
| Debt to Market Cap | 0.00 | 0.00 | 0.06 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.12 | 0.10 | 0.09 |
| Net Debt to EBITDA | 2.61 | 2.05 | 0.43 | 0.38 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -5127.77% | 94.55% | -266.35% |
| EBIT Margin | 0.00% | 0.00% | -7712.01% | -14625.85% | -476.23% |
| EBITDA Margin | 0.00% | 0.00% | -7643.91% | -14620.41% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -7712.01% | -14686.17% | -476.23% |
| Pretax Profit Margin | 0.00% | 0.00% | -7304.75% | -14625.85% | -476.88% |
| Net Profit Margin | 0.00% | 0.00% | -7304.75% | -14625.85% | -476.88% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -7304.75% | -14625.85% | -476.88% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.85% | 96.26% | 94.72% | 99.59% | 100.13% |
| Return on Assets (ROA) | -26.63% | -27.91% | -131.17% | -72.40% | -34.82% |
| Return on Equity (ROE) | -27.91% | -29.01% | -173.34% | -85.83% | -38.49% |
| Return on Capital Employed (ROCE) | -30.06% | -30.14% | -181.51% | -85.35% | -38.44% |
| Return on Invested Capital (ROIC) | -30.06% | -30.10% | -173.19% | -84.77% | -38.19% |
| Return on Tangible Assets | -26.63% | -27.91% | -131.17% | -72.40% | -34.82% |
| Earnings Yield | -23.95% | -12.21% | -280.95% | -143.22% | -55.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 3.10 | 28.15 |
| Payables Turnover | 0.00 | 0.03 | 21.06 | 0.01 | 10.42 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.88 | 0.22 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.02 | 0.00 | 0.07 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.02 | 0.00 | 0.13 |
| Cash Conversion Cycle | 0.00 | -13101.47 | -17.33 | -62380.68 | -22.05 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 117.92 | 12.97 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 13101.47 | 17.33 | 62498.61 | 35.02 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 117.92 | 12.97 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | -0.28 | -3.39 | -4.13 | -4.71 |
| Free Cash Flow Per Share | -0.28 | -0.28 | -3.39 | -4.19 | -4.71 |
| Dividend Paid and CapEx Coverage Ratio | -2074.24 | 0.00 | -1270.20 | -71.33 | 0.00 |
| Capital Expenditure Coverage Ratio | -2074.24 | 0.00 | -1270.20 | -71.33 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -173.26 | -29.08 | -49.39 | -57.44 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -69.42 | -140.56 | -4.61 |
| Free Cash Flow Yield | -13.79% | -8.49% | -267.23% | -139.57% | -53.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.18 | -2.80 | -0.36 | -0.70 | -1.81 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 26.00 | 102.12 | 8.63 |
| Price-to-Book (P/B) Ratio | 1.17 | 2.38 | 0.62 | 0.60 | 0.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.25 | -11.77 | -0.37 | -0.72 | -1.87 |
| Price-to-Operating Cash Flow Ratio | -7.25 | -11.77 | -0.37 | -0.73 | -1.87 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.04 | 0.02 | 0.05 | -0.01 |
| Enterprise Value Multiple | -1.17 | -6.15 | 0.09 | -0.32 | 0.00 |
| Enterprise Value | 62.32M | 169.05M | -1.77M | 5.77M | -13.73M |
| EV to EBITDA | -1.17 | -6.15 | 0.09 | -0.32 | 0.00 |
| EV to Sales | 0.00 | 0.00 | -6.80 | 46.73 | -4.43 |
| EV to Free Cash Flow | -2.24 | -8.83 | 0.10 | -0.33 | 0.96 |
| EV to Operating Cash Flow | -2.24 | -8.83 | 0.10 | -0.33 | 0.96 |
| Tangible Book Value Per Share | 1.76 | 1.37 | 2.06 | 5.01 | 12.66 |
| Shareholders’ Equity Per Share | 1.76 | 1.37 | 2.06 | 5.01 | 12.66 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.05 | 0.03 | 1.02 |
| Net Income Per Share | -0.49 | -0.40 | -3.57 | -4.30 | -4.87 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.90 | 1.00 | 0.95 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 52.28 | 97.50 | 3.66 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 1.92 | 3.71 | 0.49 |
| Income Quality | 0.58 | 0.70 | 0.95 | 0.96 | 0.97 |
Currency in USD

